• M S Iyikesici.
• Department of Medical Oncology, School of Medicine, Altinbas University, Bahcelievler, Istanbul, Turkey.
• Niger J Clin Pract. 2020 May 1; 23 (5): 734-740.

BackgroundSurvival outcomes are still far from being satisfactory in patients with advanced gastric cancer, despite availability of novel chemotherapeutic regimens.AimThis study evaluated the outcomes of patients with advanced gastric cancer who received chemotherapy along with additional treatment modalities targeting multiple tumor cell vulnerabilities.Materials And MethodsA total of 24 patients diagnosed with stage III-IV locally advanced or metastatic gastric adenocarcinoma that received metabolically supported chemotherapy (MSCT) combined with ketogenic diet, local hyperthermia, and hyperbaric oxygen therapy (HBOT) between April 2014 and October 2017 were included in this retrospective study. Survival outcomes were evaluated.ResultsIn 22 patients (88.0%), complete response was achieved. Mean duration of follow-up was 23.9 ± 12.7 months. Mean overall survival was 39.5 months (95% confidence interval [CI]: 28.1-51.0) and mean progression free survival was 36.5 months (95% CI: 25.7-47.2). No problems were encountered due to fasting, hypoglycemia, ketogenic diet, hyperthermia or HBOT.ConclusionsThe combination treatment used in this study (MSCT together with a ketogenic diet, hyperthermia and HBOT) appears to be promising in the treatment of advanced gastric cancer. Further research and comparative clinical trials are warranted to support and standardize this novel treatment protocol.

16 keywords...

hide…